Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service www.bestinmh.org.uk
Section for Evidence-Based Mental Health P.O. Box 32 Health Services and Population Research Department Institute of Psychiatry De Crespigny Park London SE5 8AF Tel: 020 7848 0498 Email: [email protected]Question: In adults with depression, what is the best way of swapping from fluoxetine to escitalopram, in terms of side effect profile / interactions / safe swapping over? Clarification of question: Patients = adults with depression; Intervention = change from fluoxetine to escitalopram; Comparison = none, Outcome = safe swapping over. What does the evidence say? The Maudsley prescribing guidelines 2005 –2006 (1) provides a table of guidelines concerned with swapping and stopping antidepressants. The recommendation for swapping from fluoxetine to escitalopram is: “Stop fluoxetine. Wait 4-7 days. Start citalopram/escitalopram at 10mg/day and increase slowly. Note: Advice given (in this table) is partly derived from manufacturers’ information and partly theoretical. Caution is required in every instance.”(p172) Comments From the forward to the “antidepressants – swapping and stopping” table: “ ….when switching from one SSRI to another: their effects are so similar that administration of the second drug is likely to ameliorate withdrawal effects of the first. However there is little firm evidence of this occurring”. It also stresses, “the advice given (in the following table) should be treated with caution and patients should be very carefully monitored when switching.” (p171). For further advice, please contact the medicines information service at the Maudsley, tel: 020 7919 2317.
This answer is a brief summary of the available evidence, if there is anything else you would like to know, please contact me on: [email protected] This question was received on 21st June 2006; the answer was completed on 7th July 2006 by Elizabeth Barley PhD CPsychol. This answer is > 1 year old and so may need updating. METHODS Maudsley Prescribing Guidelines(1) consulted. Reference List (1)
Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines 2005 - 2006. 8th ed. London & New York: Taylor &
Francis Group; 2005. Disclaimer
BEST in MH answers to clinical questions are for information purposes only. BEST in MH does not make recommendations. Individual health care providers are responsible for assessing the applicability of BEST in MH answers to their clinical practice. BEST in MH is not responsible or liable for, directly or indirectly, any form of damage resulting from the use/misuse of information contained in or implied by these documents. Links to other sites are provided for information purposes only. BEST in MH cannot accept responsibility for the content of linked sites.
Selbstmedikation und Transparenz - Die Rolle der Krankenkassen Dorothee Becker, Techniker Krankenkasse, 24. September 1998 __________________________________________________________ Einleitung Das Verständnis von Selbstmedikation ist häufig eindimensional und damit unzulässig verkürzt. Der Patient nimmt Symptome an sich wahr, er entscheidet selbst, nicht den Arzt aufzusuchen, er